The Conversation (0)
Ortho Dermatologics, a division of Valeant Pharmaceuticals submitted a new drug application with the FDA for IDP-118.
Ortho Dermatologics, a division of Valeant Pharmaceuticals (NYSE:VRX; TSX:VRX) submitted a new drug application (NDA) with the US Food and Drug Administration for IDP-118.
As quoted in the press release:
“We are greatly encouraged by the efficacy and safety results of the IDP-118 clinical program and proud of the dedication of our medical and R&D teams who were able to expedite the NDA filing ahead of internal expectations for this promising treatment,” said Joseph C. Papa, chairman and CEO, Valeant. “This submission reflects our unwavering commitment to investing in our pipeline to bring forward novel treatment innovations that help improve the lives of our customers and their patients.”
Both approved to treat plaque psoriasis, halobetasol propionate and tazarotene, when used separately, are limited to a four-week or less duration of use. Based on existing data from clinical studies, the combination of these ingredients in IDP-118 with a dual mechanism of action, potentially allows for expanded duration of use, with reduced adverse events.
Click here to read the full press release.
Source: www.newswire.ca
